Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Akari Therapeutics PLC (AKTX : NSDQ)

• Company Description    Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $1.13 Daily Weekly Monthly 20 Day Moving Average: 16,355 shares Shares Outstanding: 32.18 (millions) Market Capitalization: $36.36 (millions) Beta: 0.21 52 Week High: $4.40 52 Week Low: $0.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.74% -6.68% 12 Week -22.60% -32.59% Year To Date -7.38% -13.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 BOSTON WHARF ROAD FL 7 - BOSTON,MA 02210 GBR ph: 929-274-7510 fax: 646-843-9352 info@akaritx.com http://www.akaritx.com

• General Corporate Information    Officers Samir R. Patel - President and Chief Executive Officer Hoyoung Huh - Chairman Torsten Hombeck - Chief Financial Officer Ray Prudo - Director James Neal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00972G207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/18/25 Share - Related Items Shares Outstanding: 32.18 Most Recent Split Date: 8.00 (0.05:1) Beta: 0.21 Market Capitalization: $36.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -213.59 12/31/24 - -956.20 ROA 06/30/25 - - 03/31/25 - -65.60 12/31/24 - -129.47 Current Ratio 06/30/25 - - 03/31/25 - 0.16 12/31/24 - 0.15 Quick Ratio 06/30/25 - - 03/31/25 - 0.16 12/31/24 - 0.15 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.75 12/31/24 - 0.84 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©